Skip to Main Content

Paper Details

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Diabetes and Endocrinology,The
83
2021
Participants, Patients, Volanesorsen, acute pancreatitis, apolipoprotein C-III, multifactorial chlyomicronaemia, multifactorial chylomicronaemia, multifactorial chylomicronaemia syndrome, multifactorial severe hypertriglyceridaemia or familial chylomicronaemia syndrome, participant, patient, patients, platelet, serum sickness, triglyceride, triglycerides, volanesorsen
Author NameAffiliation
Daniel GaudetUniversite de Montreal
Robert A HegeleRobarts Research Institute, Western University
Sotirios TsimikasIonis Pharmaceuticals, University California San Diego
Joseph L WitztumUniversity California San Diego
  • 1 - 4

Datasets

Release 1.2